Advanced Search

 

Study ID Status Title Patient Level Data
SLGT05 Completed Assessment of the Comparability of Metered-Dose Inhaler and Dry Powder Formulations of 50mcg GR33343G, Administered Twice Daily for 2 Weeks to Patients with Mild to Moderate Reversible Airways Obstruction.
SLGT06 Completed Inhaled GR33343G in Reversible Airways Obstruction – Efficacy and Safety Over Three Months: A Double-Blind, Parallel-Group Study Comparing Dry Powder Formulations of Inhaled GR33343G (50mcg) Administered Twice a Day and Inhaled Salbutamol (400mcg) Administered Four Times a Day
SLGT09 Completed A Study to Assess the Handling of a New Dry Powder Delivery System Containing GR33343G
SLGT11 Completed Determination of the Efficacy of GR33343G (50mcg Twice Daily) Administered From a Metered-Dose Inhaler in the Elderly.
SLGT12 Completed Determination of the Efficacy of GR33343G (50mcg Twice Daily) Administered From a Metered Dose Inhaler in the Elderly.
SLGT13 Completed A Double-blind, Three-Way Crossover Study Comparing GR33343G 25mcg BID, 50mcg BID, and Placebo in the Treatment of Childhood Asthma.
SLGT39 Completed A Multi-Centre, Randomised, Double-Blind, Parallel-Group Study to Compare the Efficacy and Tolerability of Salmeterol (50mg BID) Administered by Pressurised Inhaler Propelled by a Mixture of Propellants 11 and 12 or by an Alternative Propellant, GR106642X in Adult Patients with…
SLGT40 Completed A Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Equivalence of Salmeterol 100mg Administered by Pressurised Inhaler Propelled by a Mixture of Propellants 11 and 12 or an Alternative Propellant, GR106642X in the Protection From…
SLGT41 Completed A Multi-Centre, Randomised, Double-Blind, Parallel Group Study to Compare the Efficacy and Tolerability of Salmeterol (50mg bd) Administered by Pressurised Inhaler Propelled by a Mixture of Propellants 11 and 12 or by an Alternative Propellant, GR106642X for a Period of …
SLGT42 Completed A Multi-National, Multi-Centre, Randomised, Double-Blind, Parallel Group Study to Compare the Efficacy and Tolerability of Salmeterol (50mg bd) Administered by Pressurised Inhaler Propelled by a Mixture of Propellants 11 and 12 or by an Alternative Propellant, GR106642X for…
SLGT43 Completed A Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Equivalence of Salmeterol 50mg Administered by Pressurised Inhaler Propelled by a Mixture of Propellants 11 and 12 or an Alternative Propellant, GR106642X in the Protection From…
SLM8901 Completed A Single-Dose, Double-Blind, Placebo-Controlled Cross-over Study to Determine the Efficacy and Duration of Action of Inhaled Salmeterol Xinafoate 50mcg Against Methacholine-Induced Bronchoconstriction in Children with Reversible Airways Obstruction
SLMF4003 Completed Contribution of salmeterol in uncontrolled asthma in children
SLMF4010 Completed Multicentre, randomised, parallel group, placebo-controlled, double-blind, study, stratified on tobacco status at enrollment, evaluating during 6 months the efficacy of salmeterol powder for inhalation, 50 μg two times per day for the reduction of thoracic distension in subjects with chronic obstructive pulmonary disease (COPD)
SLMP03 Completed A single centre, randomised, double-blind, parallel group, placebo controlled study, to evaluate the effect of inhaled salmeterol xinafoate (50micrograms bd from a Diskhaler) on variations in bronchoconstriction induced by methacholine, in paediatric patients with mild to moderate asthma.
SLMT02 Completed Efficacy, Safety and Quality of Life of Inhaled Salmeterol 50mcg BID and Oral Dose Titrated Theophylline Administered 12 Hourly in Patients With Chronic Bronchitis
SLPT01 Completed A Multicentre, Randomized, Double-Blind, 3-Limbed, Parallel-Group Study Comparing the Efficacy and Tolerability of Salmeterol Xinafoate 25?g and 50?g BID With Salbutamol 200?g BID Given via Pressurized Inhalers in Children With Reversible Airways Obstruction. (3-Month Efficacy and Safety Study.)
SLPT02 Completed A Multi-centre, Randomised, Double-Blind, 3-Limbed, Parallel-Group Study Comparing the Efficacy and Tolerability of Dry Powder Formulations of Salmeterol Xinafoate 25?g and 50?g Twice Daily With Salbutamol 200?g Twice Daily Given in Children With Reversible Airways Obstruction
SLPT03 Completed A Multicentre, Randomised, Double-Blind, Parallel-Group Study Comparing Pressurised Inhaler and Dry Powder Formulations of Salmeterol Xinafoate 50?g bd in Children With Reversible Airways Obstruction
SLPT18 Completed A Multi-Centre, Multi-National, Randomised, Double-Blind, Parallel Group Study to Compare the Efficacy and Tolerability of Salmeterol (50mg BID) Administered by Pressurised Inhaler Propelled by a Mixture of Propellants 11 and 12 or by an Alternative Propellant, GR106642X for a Period of…
SM030003 Completed A Single-Centre, Randomised, Placebo-Controlled, Double-Blind, 3-Way Crossover Proof-of-Concept Study to Evaluate the Effect of Reduced Fine Particle Mass (FPM) From the Salmeterol 50mg GR106642X Metered Dose Inhaler Compared With Salmeterol 50mg P11/12 Metered Dose Inhaler on…
SMDT01 Completed A Double-Blind, Double-Dummy, Randomised Crossover Study to Compare the Effect of a Single 50?g Dose of Salmeterol Administered via the Multidose Powder Inhaler (MDPI) or Diskhaler Dry Powder Inhaler With Placebo in Adult Patients With Reversible Airways Obstruction
SMDT02 Completed A Multi-Centre, Randomised, Double-Blind, Double-Dummy, Parallel-Group Study to Determine the Clinical Equivalence of Salmeterol Xinafoate 50mg Twice Daily Delivered via a Multi-dose Powder Inhaler (MDPI) or ROTADISK/DISKHALER in Adolescent and Adult Patients With Reversible Airways Disease
SMK20001 Completed A Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group, Dose Response Evaluation of a New Chemical Entity (NCE) and ZYBAN (bupropion hydrochloride) Sustained Release (300mg/day) versus Placebo As Aids to Smoking Cessation.
SMO30006 Completed A Multi-Centre, Randomised, Double-Blind, 12-Week, Parallel-Group Study to Compare Salmeterol Xinafoate 50mcg BD Delivered Either via a HFA Metered-Dose Inhaler or via a CFC Metered-Dose Inhaler, in the Treatment of Adults, Aged 12 years and Over, With Asthma Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.